BELLUS Health Inc.
BLU
$0.01
Change (1 day)
$14.76
Year High
$6.38
Year Low
Categories
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Earnings for BELLUS Health Inc. (BLU)
Earnings in 2022 (TTM): $-76,020,000
According to BELLUS Health Inc.'s latest financial reports the company's current earnings (TTM) are $-76,020,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of BELLUS Health Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2022 | $-76,020,000 | $-76,080,000 |
| 2021 | $-71,423,000 | $-71,224,000 |
| 2020 | $-31,757,000 | $-31,796,000 |
| 2019 | $-26,385,051 | $-26,408,017 |
| 2018 | $-6,669,457 | $-6,062,275 |
| 2017 | $-1,441,750 | $-1,490,258 |
| 2016 | $-1,646,455 | $-1,606,279 |
| 2015 | $272.4 K | $145.57 K |
| 2014 | $-1,737,505 | $-1,663,422 |
| 2013 | $-911,934 | $-818,956 |
| 2012 | $-13,238,443 | $-13,323,884 |
| 2011 | $3.58 M | $3.35 M |
| 2010 | $-19,734,842 | $-20,109,782 |
| 2009 | $-8,227,000 | $-8,227,000 |
| 2008 | $-48,223,000 | $-48,223,000 |
| 2007 | $-81,073,000 | $-81,073,000 |
| 2006 | $-64,676,361 | $-64,676,361 |
| 2005 | $-62,309,759 | $-62,309,759 |
| 2004 | $-43,587,775 | $-43,587,775 |
| 2003 | $-13,300,121 | $-12,934,564 |
| 2001 | $-8,732,608 | $-8,885,592 |
| 2000 | $ | $-1,775,355 |
| 1999 | $-3,995,544 | $-3,768,018 |